title: Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes.
abstract: METHODS
  Glucose-Lowering Effect of Welchol Study (GLOWS) was a randomized, double-blind, placebo-controlled trial to examine the effects of colesevelam HCl on glycemic and lipid control in type 2 diabetes patients with HbA1c (A1C) between 7.0% and 10.0%. After a 4-week placebo lead-in period, 65 subjects (31 colesevelam, 34 placebo) were randomized to receive colesevelam 3.75 g/day or matching placebo for 12 weeks in addition to maintaining their previous oral antihyperglycemic regimen (metformin, sulfonylurea, or both). Lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy were secondary efficacy variables evaluated in 56 subjects (26 colesevelam, 30 placebo) at baseline and week 12.
  
  
  RESULTS
  Previously published data demonstrated that colesevelam resulted in significant reductions in LDL-C, and Apo B. This analysis demonstrates that relative to placebo, colesevelam treatment reduced mean total LDL particle concentration (LDL-P) by 15.5% (-242 nmol/L [-412,-72], p=0.006) primarily due to lowering in small LDL-P (-207 nmol/L [-418,4], p=0.054) and a lesser reduction in large LDL-P [-30 nmol/L [-118,58], p=0.496) and IDL-P (-5 nmol/L [-21,11], p=0.557).
  
  
  CONCLUSIONS
  In type 2 diabetes patients, colesevelam improves glycemic status and reduces the concentration of LDL-C and LDL-P with little change in concentrations of other lipoprotein particles.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Rosenson
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Abby
authors.forename: Michael R
authors.initials: MR
authors.lastname: Jones
mesh_terms: D000368:Aged; D000499:Allylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D000069472:Colesevelam Hydrochloride; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood*; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D010316:Particle Size; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000499:Allylamine; D000924:Anticholesteremic Agents; D015415:Biomarkers; D000069472:Colesevelam Hydrochloride; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008074:Lipoproteins; D008687:Metformin; D013453:Sulfonylurea Compounds; C517652:hemoglobin A1c protein, human